The record assembles itself. The oncologist reviews it.

Saltgrass AI is a clinical intelligence platform built for oncology. Synopsis, its first product, turns a decade of scattered records into a single decision-ready summary — and it is live in production at MUSC Hollings Cancer Center.

  • Canonical FHIR R4
  • HIPAA-compliant architecture
  • Live at MUSC Hollings
Synopsis Oncology patient summary Synthetic data

Interface shown with synthetic data.

Before anyone can make a decision, someone has to read all of it.

A new oncology patient arrives with a decade of history, scattered across outside records, scanned faxes, pathology reports and imaging from four different systems.

Hours of chart abstraction go into every new-patient visit, every tumor board and every prior authorization. It delays treatment, and it consumes the most expensive time in the health system.

Outside records
Faxes & scans
Pathology
Imaging
No single view of the record
New patient visit
Tumor board
Prior authorization

The same unread record, at every point along the patient journey.

Above the electronic health record, not in place of it.

Saltgrass AI ingests, normalizes and reasons over patient data through a canonical FHIR R4 model inside a HIPAA-compliant architecture. It reads from the systems a cancer program already runs, and returns the structure those systems were never designed to produce.

Products

SynopsisLive
Prior authorization
Clinical trial matching
Federated data services
  • Canonical FHIR R4 model
  • SMART on FHIR
  • HIPAA-compliant architecture
Systems of record
EHR
PACS / imaging
Outside records
Faxes & scans

Synopsis is the first product on the platform.

It turns a fragmented longitudinal record into a single, decision-ready oncology summary — organized the way an oncologist actually reads a chart.

Synopsis product overview — from the unread record to a decision-ready summary. Captioned · shown with synthetic data

The record as it actually exists

Synopsis takes structured data, unstructured notes and scanned documents in whatever form the record arrives, applying optical character recognition to anything that is not already machine-readable.

Structured data
Unstructured notes
Scanned documents

Live at MUSC Hollings Cancer Center

  • The cancer program of the Medical University of South Carolina, a top-tier academic medical center.
  • Ranked No. 1 in South Carolina for cancer care, 2026–2027.
  • The only NCI-designated cancer center in South Carolina.

Synopsis is in production there today.

Chart preparation that consumed most of a morning is ready before clinic starts.

The clinician's role shifts from assembling the record to reviewing it.

Before

Assembling the record

Sources pulled, read and abstracted by hand ahead of every encounter.

With Synopsis

Reviewing it

Diagnosis & staging
Pathology & biomarkers
Treatment history
Imaging & response

A structured summary, ready before clinic starts.

Observed at MUSC Hollings Cancer Center
TaskBeforeWith SynopsisReduction
Chart creation70 min10 min86%
Summary review60 min15 min75%
Prior-authorization documentation45 min20 min56%
Per new-patient encounter175 min45 min74%
1,200Patients supported today, scaling to 12,000
95%Clinically accurate in a PhD study of 300+ reports
3,750Physician hours saved in year one
5,000New patients of released capacity

Figures observed in production use at MUSC Hollings Cancer Center.

A defensible position, from the clinic outward.

The technology was not built to demonstrate what a model can do. It was built inside a cancer program, to solve a problem that program had.

  • Exclusively licensed core technology

    The core summarization and harmonization technology originated in clinical practice at MUSC and is exclusively licensed to Saltgrass AI by the Zucker Institute for Innovation Commercialization.

  • Platform data models and infrastructure

    The canonical FHIR R4 data model, the ingestion and harmonization pipeline, and the HIPAA-compliant architecture every product runs on.

  • Clinical logic built on top

    Indication-specific prompts, schemas and output structures authored by practising oncologists, and the provenance layer that ties each assertion to its source.

Together, these form the company's intellectual property position.

One platform, one patient model, more than one product.

Once the record is harmonized, the same clinical data model serves the workflows that surround it.

  • Live

    Synopsis

    Decision-ready oncology summaries and clinical timelines, traceable to source.

  • On the roadmap

    Prior authorization

    Payer-ready documentation assembled from the same harmonized record.

  • On the roadmap

    Clinical trial matching and enrollment

    Structured eligibility signals surfaced at the point the decision is made.

  • On the roadmap

    Federated data services

    Research-grade oncology data, harmonized across institutions.

About us

Built by clinicians and operators, inside a cancer program.

Saltgrass AI began with a team of clinicians at the Medical University of South Carolina, led by Dr. Kevin Hughes, who set out to reduce the administrative burden on oncologists while improving clinical efficiency, quality and throughput.

Their idea was to automate the manual review of faxed documents and patient charts — work that had required hours of human interpretation and was prone to error — and produce an accurate, structured summary that prepares physicians for a first-time patient encounter. That work now supports MUSC’s Next Day Access program and speeds time-to-treatment across Hollings Cancer Center.

Today the company pairs that clinical origin with operators who have scaled healthcare and data companies through IPOs, acquisitions and enterprise-wide AI adoption, with one aim: make healthcare intelligence usable, so clinicians can act on it with confidence.

  • Robert Goodman

    Robert Goodman

    Chief Executive Officer

    Robert has spent more than 20 years leading AI, data and digital health transformation, taking enterprise-scale AI from strategy to production and guiding companies through IPOs and private-equity exits.

    • Chief Data & AI Officer at Blue Cross Blue Shield of Minnesota, embedding AI enterprise-wide and partnering to launch Xcelerate Health
    • Global VP of Analytics at Ellucian, leading the data overhaul behind its $5B+ private-equity sale
    • Built Deloitte’s Insight Studio, a national AI innovation hub serving Fortune 500 clients
    • Helped scale Blackbaud through its NASDAQ IPO
  • Brian Litten

    Brian Litten

    Board of Directors · Healthcare Industry Advisor

    Brian brings more than 25 years shaping digital health, value-based care and healthcare AI. He is a proven operator who has led IPOs, M&A and high-value growth outcomes.

    • Scaled Tabula Rasa HealthCare from startup to $300M+ in recurring revenue and a NASDAQ IPO
    • Delivered $62M+ in first contracts and $100M+ in post-IPO growth deals
    • Founded and led a company through its exit to a Fortune 100 acquirer
    • Turned around Swift Medical with a $13M bridge raise and technology reboot
  • Dr. Kevin Hughes

    Dr. Kevin Hughes

    Board of Directors · Clinical Advisor

    Dr. Hughes is Director of Cancer Genetics at MUSC and led the team of clinicians from which Synopsis originated. He has spent more than 30 years leading breast cancer diagnosis, treatment and clinical research.

    • Former Massachusetts General Hospital breast surgeon and Co-Director of the Avon Breast Center; Professor Emeritus, Harvard Medical School
    • International expert in hereditary breast cancer and the clinical use of genetic testing
    • Recognized for minimal-intervention, precision approaches that improve outcomes and early detection
    • Co-founder of CRA Health, acquired by Volpara

Improving clinical outcomes for oncology.

Saltgrass AI works with cancer programs that want their clinicians reading the record instead of assembling it. Briefings cover the platform architecture, the MUSC deployment and what a first indication looks like at your institution.